Introduction to Liquid Biopsy in Ovarian Oncology

Ovarian cancer remains the most lethal malignancy among gynecological diseases. Consequently, clinicians urgently need more precise biomarkers for early detection and management. Recent research highlights the transformative potential of ctDNA in ovarian cancer as a non-invasive tool. Unlike traditional serum markers, circulating tumor DNA (ctDNA) provides a real-time snapshot of the tumor's genetic profile. Therefore, it offers a promising avenue for improving patient outcomes through precision medicine.

Clinical Applications of ctDNA in Ovarian Cancer

The application of ctDNA in ovarian cancer spans several critical stages of patient care. In early screening, it provides higher specificity than CA-125, especially in detecting early-stage tumors. Furthermore, ctDNA plays a vital role in monitoring minimal residual disease (MRD) after primary surgery. By detecting molecular relapse months before imaging, it allows for earlier intervention. Moreover, clinicians can use ctDNA to predict treatment responses and tailor personalized therapies. This approach ensures that patients receive the most effective drugs based on their unique mutational landscape.

Challenges and Future Directions

While the potential is enormous, several technical hurdles remain. Currently, the sensitivity for very early-stage detection is still being optimized. Additionally, there is a lack of global standardization in detection methods across laboratories. However, future research aims to integrate ctDNA with other biomarkers to enhance diagnostic accuracy. As technology improves, liquid biopsy will likely become a standard part of routine clinical practice for managing gynecological malignancies.

Frequently Asked Questions

How does ctDNA compare to CA-125 in ovarian cancer?

ctDNA offers superior sensitivity and specificity compared to CA-125. Specifically, it can detect molecular changes and recurrence much earlier than traditional protein markers or imaging.

What is the benefit of MRD monitoring with ctDNA?

Monitoring minimal residual disease (MRD) with ctDNA identifies patients at high risk of relapse after surgery. This allows doctors to adjust adjuvant therapy and potentially improve long-term survival rates.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Abulajiang Y et al. The role of circulating tumor DNA in ovarian cancer. Discov Oncol. 2026 Jun 04. doi: 10.1007/s12672-026-05333-1. PMID: 42237054.

2. Martinelli C et al. Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice. J Exp Clin Cancer Res. 2025;44(1):140. doi: 10.1186/s13046-025-03371-1.

3. Wang J et al. Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer. J Clin Oncol. 2024;42(16_suppl):5525. doi: 10.1200/JCO.2024.42.16_suppl.5525.